HR1525-119

In Committee

Protecting Life from Chemical Abortions Act

119th Congress Introduced Feb 24, 2025

Summary

What This Bill Does

The Protecting Life from Chemical Abortions Act directs HHS and FDA not to exercise enforcement discretion for abortion-drug Risk Evaluation and Mitigation Strategy requirements. It requires reinstatement of in-person dispensing in clinics, medical offices, or hospitals under the supervision of a certified provider, and it blocks the agencies from reducing REMS protections without meeting the bill's legal conditions. The bill therefore reverses the policy direction of telehealth and mail-order abortion-drug access. It benefits groups seeking tighter abortion-drug controls while imposing direct access burdens on medication-abortion patients, telehealth abortion providers, pharmacies, and FDA administrators.

Who Benefits and How

Anti-abortion advocacy organizations benefit because FDA would have to enforce stricter abortion-drug safeguards rather than relying on discretion. Clinics favoring in-person supervision benefit because mifepristone dispensing would be routed back to clinics, medical offices, or hospitals. State abortion regulators benefit from a federal requirement aligned with stricter in-person medication-abortion oversight. Certified providers who offer in-person visits benefit from a rule that channels abortion-drug dispensing through supervised settings.

Who Bears the Burden and How

Medication-abortion patients bear higher travel, scheduling, privacy, and access burdens when in-person dispensing is required. Telehealth abortion providers lose the ability to rely on mail-order or remote dispensing models covered by enforcement discretion. Pharmacies dispensing abortion drugs face restrictions if they cannot satisfy the reinstated REMS framework. FDA administrators must reverse enforcement policies, update REMS requirements, and police compliance.

Key Provisions

  • Requires HHS and FDA to enforce abortion-drug REMS requirements.
  • Reinstates in-person dispensing in clinics, medical offices, or hospitals under certified provider supervision.
  • Blocks enforcement discretion that would waive or soften abortion-drug safeguards.
  • Restricts future agency reductions of REMS protections without satisfying statutory conditions.

Evidence Chain:

This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers.

At a Glance

What This Bill Does

Requires HHS and FDA to enforce abortion-drug REMS safeguards, reinstate in-person dispensing by certified providers, and bars reducing those requirements without statutory compliance.

Key Policy Areas

Health Care, FDA, Reproductive Policy

Primary Purpose

Requires HHS and FDA to enforce abortion-drug REMS safeguards, reinstate in-person dispensing by certified providers, and bars reducing those requirements without statutory compliance.

Policy Domains

Health Care FDA Reproductive Policy

Resolution provisions

Identified Gains
Contextual inference, no direct clause citation
  • Anti-abortion advocacy organizations
  • In-person abortion clinics
  • State abortion regulators
  • Certified providers
Model: codex-gpt-5 | Version: bill_summary_v2 | Source: ih

Contextual inference, no direct clause citation

Identified Costs
Contextual inference, no direct clause citation
  • Medication-abortion patients
  • Telehealth abortion providers
  • Pharmacies dispensing abortion drugs
  • FDA
Model: codex-gpt-5 | Version: bill_summary_v2 | Source: ih

Contextual inference, no direct clause citation

Legislative Progress

In Committee
Introduced Committee Passed
Feb 24, 2025

Mr. Hern of Oklahoma (for himself, Mr. Aderholt, Mr. Feenstra, …

Feb 24, 2025

Referred to the House Committee on Energy and Commerce.

Feb 24, 2025

Introduced in House

Stakeholder Effects

cui bono?

How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.

Healthcare
2 mentions across 1 clause
+1 positive -1 negative

In-person abortion clinics, Medication-abortion patients

Positive-direction: In-person abortion clinics

Negative-direction: Medication-abortion patients

Nonprofits
1 mention across 1 clause
?1 uncertain

Anti-abortion advocacy organizations

Digital Health
1 mention across 1 clause
-1 negative

Telehealth abortion providers

Government
1 mention across 1 clause
-1 negative

FDA

1/3
sections analyzed
Full impact breakdown

Bill Structure & Actor Mappings

Who is "The Secretary" in each section?

Domains
Health Care FDA Reproductive Policy

We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.

Learn more about our methodology